Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8% | news.google.com • |
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA) | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8% | news.google.com • |
(SAVA) Technical Pivots with Risk Controls | news.google.com • |
Is Sava, druzba za upravljanje in financiranje, d.d.'s (LJSE:SAVR) Stock Price Struggling As A Result Of Its Mixed Financials? | news.google.com • |
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference | globenewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -1.37 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.44 | -1.28 | -0.84 | -190.91% |
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
-
-
-
-
Cassavas PTI125 study shows that PTI125 has a significant affect on the reduction of neuro inflammation. Neuro inflammation is the primary precursor to the onset of Alzheimer’s. IMO, PTI125 is a blockbuster drug, just due to its effect on neuro inflammation and the prevention of Alzheimers.
PTI-125 significantly reduced a secondary endpoint, CSF levels of IL1-beta (p<0.035), a core biomarker of neuroinflammation, from baseline to Day 28. Drug was safe and well-tolerated.
**In Alzheimer's disease (AD) neuroinflammation, instead of being a mere bystander activated by emerging senile plaques and neurofibrillar tangles, contributes as much or more to the pathogenesis as do the plaques and tangles themselves 1. This is underlined by recent findings that genes for immune receptors, including TREM2 2 and CD33 3,4, are associated with AD. Analysis of clinical manifestations that precede AD, such as mild cognitive impairment (MCI), further argue for an early and substantial involvement of inflammation in the pathogenesis of the disease.
-
-
-
my price 2.80 lol
-
-
-
-
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8%
news.google.com • -
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA)
news.google.com • -
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8%
news.google.com • -
(SAVA) Technical Pivots with Risk Controls
news.google.com • -
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com • -
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
marketbeat.com • -
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
seekingalpha.com • -
2 Biotech Stocks Making Moves Today
schaeffersresearch.com • -
Cassava Sciences News: Why Is SAVA Stock Trending Today?
investorplace.com • -
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
globenewswire.com • -
Get Your Money Out of These 3 Healthcare Stocks ASAP
investorplace.com • -
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
investorplace.com • -
Cassava Sciences Announces Expansion of Open-Label Extension Trials
globenewswire.com • -
Get Your Money Out of These 3 Biotech Stocks Before the End of July
investorplace.com • -
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
investorplace.com • -
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
investorplace.com • -
3 Healthcare Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Top 5 Health Care Stocks That May Explode In July
benzinga.com • -
3 Biotech Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Why Cassava Sciences Stock Is Sinking Today
fool.com •